Novartis/QLT Visudyne adds indications
This article was originally published in Pharmaceutical Approvals Monthly
Verteporfin receives clearance for two new indications Aug. 22 - use in pathologic myopia and presumed ocular histoplasmosis. The new label also adds 24-month data on treatment of predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, as well as updated information in the "adverse reactions" section. Visudyne sales in 2000 reached $100 mil. worldwide. QLT is projecting sales of $225 mil. to $250 mil. this year, assisted by the expanded indications. Novartis and QLT are testing other indications including AMD dominated by occult CNV, minimally classic CNV secondary to AMD, and non-melanoma skin cancer
You may also be interested in...
Germany’s Merck KGaA rapidly expanded its life sciences services business to support the manufacture of COVID-19 vaccines during 2020, and also expects cancer and multiple sclerosis products to fuel its sales growth in coming years.
Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.
A detailed report published by Medicines for Europe setting out policies affecting the off-patent industry across 22 European countries demonstrates the urgent need for pricing and reimbursement and procurement reforms, the association insists.